Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 3. Glucose uptake increased by Acebutolol in insulin target cell lines. The levels of glucose uptake were detected by fluorescent glucose analog, 2-NBDG. (A) HepG2 cells were treated with 100 nM insulin (Ins), 1 μM BI-78D3 (BI), 1 μM Acebutolol (AC) or vehicle (None) for 1 h after incubation of TNFa (20 ng/ml) for 6 h or not treated with TNFa. (B) Differentiated 3T3L1 cells and (C) HepG2 cells were treated with 100nM insulin (Ins), 1 μM BI-78D3 (BI), 1 μM Acebutolol (AC) or vehicle (None) for 1 h after treatment of TNFα 20 ng/ml for 6 h. (D) HepG2 cells were treated with 0.5 μM, 1 μM, or 5 μM Acebutolol (AC) or vehicle (None) for 1 h after incubation of TNFα (20 ng/ml) for 6 h or not treated with TNFα. The Bar graph shows the mean folds of the fluorescence intensity of insulin, BI-78D3 or Acebutolol-treated versus vehicle-treated cells. The experiment was repeated three times independently and four cell samples for one treatment conditions were used in each time of repeat. Statistical analysis was assessed by one-tailed unpaired t-test; n=3; *p<0.05, **p<0.01, ***p<0.001 vs. vehicle (None).
Biomolecules & Therapeutics 2018;26:458~463 https://doi.org/10.4062/biomolther.2017.123
© Biomolecules & Therapeutics